Publication Name	World Journal of Transplantation
Manuscript ID	39945
Country	Japan

Received	2018-05-21 02:12
Peer-Review Started	2018-05-21 08:08
To Make the First Decision	2018-06-06 07:36
Return for Revision	2018-06-08 01:24
Revised	2018-06-23 07:40
Second Decision	2018-06-26 12:32
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2018-06-28 04:04
Articles in Press	2018-06-28 04:04
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-09-06 04:09
Publish the Manuscript Online	2018-09-07 06:15

ISSN	2220-3230 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Transplantation
Manuscript Type	Minireviews
Article Title	Introduction of everolimus in kidney transplant recipients at a late posttransplant stage
Manuscript Source	Invited Manuscript
All Author List	Junji Uchida, Tomoaki Iwai and Tatsuya Nakatani
ORCID	Author(s) ORCID Number Junji Uchida http://orcid.org/0000-0002-0113-8058 Tomoaki Iwai http://orcid.org/0000-0003-2021-0673 Tatsuya Nakatani http://orcid.org/0000-0002-0753-1571
Funding Agency and Grant Number
Corresponding Author	Junji Uchida, MD, PhD, Associate Professor, Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3, Abeno-ku, Asahi-machi, Osaka 545-8585, Japan. m9492120@msic.med.osaka-cu.ac.jp
Key Words	Kidney transplantation; Everolimus; mTOR inhibitor; Late conversion; Calcineurine inhibitor
Core Tip	Current immunosuppressive protocols consisting of calcineurin inhibitors (CNIs) and mycophenolate mo­fetil have improved short-term graft survival. However, improvements in long-term graft survival are restricted by nephrotoxicity associated with CNI. Everolimus is an exceedingly useful immunosuppressant for kidney transplant recipients when administered in combination with low-dose CNIs or with elimination of CNIs. Here, we summarize the current knowledge about the introduction of everolimus with CNI elimination or minimization in kidney transplant recipients at late posttransplant stage.
Publish Date	2018-09-07 06:15
Citation	Uchida J, Iwai T, Nakatani T. Introduction of everolimus in kidney transplant recipients at a late posttransplant stage. World J Transplant 2018; 8(5): 150-155
URL	http://www.wjgnet.com/2220-3230/full/v8/i5/150.htm
DOI	http://dx.doi.org/10.5500/wjt.v8.i5.150

Full Article (PDF)	WJT-8-150.pdf
Manuscript File	39945-Review.docx
Answering Reviewers	39945-Answering reviewers.pdf
Audio Core Tip	39945-Audio core tip.MP3
Conflict-of-Interest Disclosure Form	39945-Conflict-of-interest statement.pdf
Copyright License Agreement	39945-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	39945-Language certificate.pdf
Peer-review Report	39945-Peer-review(s).pdf
Scientific Misconduct Check	39945-Scientific misconduct check.pdf
Scientific Editor Work List	39945-Scientific editor work list.pdf